- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Nicole Rosendale: Data Lagging in Neurologic Care for LGBTQ+ Individuals
Nicole Rosendale, MD, assistant professor of neurology at the University of California San Francisco, neurologist/neurohospitalist, discusses how many unknowns prevail in data concerning neurologic care for LGBTQ+ individuals.
Multiple unknowns are still present in data among LGBTQ+ individuals seeking neurologic care, says Nicole Rosendale, MD, assistant professor of neurology at the University of California San Francisco, neurologist/neurohospitalist.
Transcript
What are some of the greatest health-related neurological needs in the LGBTQ+ community?
I think this is a really important question and one where, unfortunately, we don't have a great answer at this point in time. There's certainly a lot more research that needs to be done. The challenge right now is that because data sources are so limited, not everyone is asking folks their sexual orientation or gender identity in a systematic way. There's a lot that we don't know. I was able to do a scoping review that was published in 2021 that tried to summarize a little bit of the current science of LGBTQ health in neurology, and there was a suggestion that there are certain disparities, particularly in terms of prevalence of certain conditions, such as stroke, for example, and conditions such as functional neurologic disorders, potentially, but there's many, many answers that we don't know and many areas of neurology that still need coverage.
Disparities in Telehealth Access Undermine Adoption Among Patients With Schizophrenia
January 16th 2025The COVID-19 pandemic accelerated the widespread adoption of telemental health care, and new research indicates significant racial and ethnic disparities in access to this technology among Medicaid beneficiaries with schizophrenia.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
The study found significant disparities in the exposure to contaminants. Communities with higher percentages of Hispanic and Black residents were not only more likely to have unregulated chemicals in their drinking water, but they were also more frequently located near pollution sources.
Read More
